Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT03666000 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma
B-cell Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Azer-cel
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: IL-2

Sponsor

Imugene Limited